[Alzheimer's Association](https://www.alz.org)

August 6, 2025 (Letter of Intent) | September 24, 2025 (Full Application, by invitation)

Up to $1,000,000 total (direct + indirect) over 2–3 years; indirect costs capped at 10% for nonprofits, not allowed for for-profits.

Supports late-stage preclinical development of innovative Alzheimer’s disease therapeutics to accelerate their transition into clinical trials.

--- ## Description The Alzheimer's Association's Part the Cloud Enable the Molecule for Therapeutics (PTC-EMT) Funding Program is designed to accelerate the development of promising therapeutics for Alzheimer’s disease and related dementias. This program specifically funds projects at the IND-enabling stage, supporting comprehensive preclinical evaluation (including pharmacology, toxicology, biodistribution, formulation, and manufacturing scale-up) for rigorously characterized therapeutic candidates. The ultimate goal is to expedite the transition of innovative small molecules, biologics, gene therapies, and other modalities into clinical trials, bridging a critical funding gap and moving scientific discoveries closer to clinical application. --- ## Due Dates - **Letter of Intent (LOI) deadline:** August 6, 2025 (must be received by 5:00 PM Eastern Time) - **Full application deadline (by invitation):** September 24, 2025 (must be received by 5:00 PM Eastern Time) Both deadlines are strict; late, hard copy, or email submissions will not be accepted. --- ## Funding Amount - **Maximum award:** Up to $1,000,000 total (inclusive of direct and indirect costs) over two or three years. - **Indirect costs:** Allowed only for not-for-profit institutions, capped at 10%. No indirect costs allowed for for-profit organizations. - **Budget evaluation:** Budgets must be appropriate for the proposed study; detailed justifications required. --- ## Eligibility - Open to investigators from non-profit academic institutions and small for-profit companies (special consideration for companies with fewer than 50 staff). - Principal Investigator (PI) must hold a full-time, paid position at the applying institution; postdoctoral researchers and those in non-permanent roles are not eligible. - International applicants are welcome, subject to U.S. law and sanctions. - Organizations must provide documentation of their status. - Proposals from individuals or entities under U.S. sanctions or on the Specially Designated Nationals list are not eligible. --- ## Application Process 1. **Letter of Intent (LOI):** - Submit via [ProposalCentral](https://proposalcentral.com/). - Requires PI/institution details, project title and summary, ORCID ID, signed W9/W8, and PI biosketch. - No budget required at this stage. - LOIs are reviewed for eligibility and program fit; only selected applicants will be invited to submit a full application. 2. **Full Application (by invitation only):** - Must be submitted through ProposalCentral by the deadline. - Required sections: executive summary, research strategy, preliminary data, target product profile, team qualifications, milestone plan, detailed budget and justification, IP/commercialization plan, and data management/sharing plan. - Late or incomplete applications will not be considered. 3. **Review Process:** - Scientific and technical review in October–November 2025. - Funding notifications anticipated by November 15, 2025. --- ## Additional Information - Supported activities must be strictly within the IND-enabling stage; discovery-phase or clinical trial activities are not eligible. - Only disease-modifying therapeutic approaches are considered (not symptomatic treatments). - Projects must include clearly defined milestones and deliverables. - Data sharing with Alzheimer’s Association-approved repositories is required. - Certain costs are not allowed (e.g., capital equipment, tuition, rent for lab/office space, general liability insurance, computer hardware/software for investigators). --- ## External Links - [Program Overview & Guidelines](https://www.alz.org/research/for_researchers/grants/types-of-grants/part-the-cloud-emt-funding-program) - [2026 PTC-EMT RFA (PDF)](https://www.alz.org/getmedia/d30748e8-bdf0-48db-a3f9-970722cb351b/2026-ptc-emt-rfp.pdf) - [ProposalCentral Application Portal](https://proposalcentral.com/) --- ## Contact Information | Purpose | Contact | |--------------------------|---------------------------------------------| | General Inquiries | grantsapp@alz.org | | Funder Website | [https://www.alz.org](https://www.alz.org) | | Phone | +1 800-272-3900 | | Application Portal Help | [ProposalCentral](https://proposalcentral.com/) |

2026 Part the Cloud Enable the Molecule for Therapeutics (PTC-EMT) Funding Program

Sign in to see full grant listing